Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YS247 in HRD-negative Epithelial Ovarian Cancer
NCT07455071Not yet recruiting
- Sponsor
- Peking University Third Hospital
- Start
- Mar 2026
- Primary completion
- Sep 2027
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
01
Overview
Open-label, single-arm trial of YS247 in epithelial ovarian cancer (EOC), sponsored by Peking University Third Hospital. Primary endpoints: Safety and Tolerability of YS247 at 12 months and Maximum Tolerated Dose at 12 months. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
YS247
03
Conditions
epithelial ovarian cancer (EOC)
Beyond the preview
Go deeper on NCT07455071.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07455071.